Innovation driving the future of diagnostics

Advancing diagnostic technologies through research, collaboration and scientific expertise to meet emerging healthcare needs.

Shaping the future of diagnostics

From scientific discovery to real-world diagnostic solutions, we innovate through research, collaboration and technological expertise.

Scientific excellence, technological innovation, applied R&D, and collaborative partnerships enable us to develop diagnostic technologies that address emerging healthcare challenges. Through technology transfer, knowledge exchange, and continuous improvement, we transform scientific advances into solutions that create lasting value for healthcare professionals, industry partners, and patients worldwide. Technology intelligence and intellectual property management further strengthen our ability to anticipate future needs and drive sustainable innovation.

Certest is the winner of the National Innovation and Design Awards granted by the Ministry of Science and Innovation.

129

R&D Personnel (2024)

50

Number of PhDs

14

Patents

6.4M€

R&D investment (2024)

ISO 13485

certified QMS

89 IVDR

certified products

Resources and capabilities

Interdisciplinary teams

Our R&D and innovation teams are composed of highly qualified specialists with academic backgrounds in a wide range of scientific fields, including chemistry, biotechnology, biochemistry, nanotechnology, and bioinformatics. Over 40% of our R&D staff hold PhDs or bachelor's degrees.

Facilities, laboratories and equipment

Certest has over 26,000 m² allocated to facilities and laboratories, being one of the largest areas in Europe dedicated to biotechnology. Our facilities house state-of-the art laboratories and cutting-edge equipment, empowering us to spearhead pioneering solutions for both the IVD and biopharmaceutical sectors.

Full product lifecycle

We cover the full product lifecycle, from design to commercialization. Our success is deeply rooted in our knowledge, expertise, and the ability to self-source critical raw materials, ensuring us a consistent supply and independence from third parties.

Industry 4.0

We are in a state of continuous evolution, proactively enhancing our competitiveness by embracing new technologies such as automation, digitalization, AI, bioinformatics, and data analytics. This technological transformation empowers us to streamline our processes, enabling us to respond to market demands swiftly and efficiently with a personalized touch.

Alliances and collaborations

We forge strategic partnerships with both public and private organizations to tackle new challenges and foster the generation of innovative ideas, driving the development of groundbreaking solutions.

Research Areas

Infectious Diseases & AMR

Advanced Molecular Diagnostics

Pharmacogenomics & Personalized Medicine

Nucleic Acid Therapeutics

Bioinformatics & AI

Infectious Diseases and Antimicrobial Resistance

We develop innovative solutions for the detection of infectious diseases and antimicrobial resistance, spanning the entire in vitro diagnostics value chain: from next-generation monoclonal antibodies as critical raw materials to rapid tests, chemiluminescence immunoassays (CLIA) and molecular diagnostics. We also explore novel RNA-based therapeutic strategies and lipid nanoparticle (LNP) delivery systems targeting priority pathogens, with a particular focus on combating antimicrobial resistance and strengthening preparedness for future biological threats.

Advanced Molecular Diagnostic Technologies

We are developing a proprietary, next-generation, interoperable real-time PCR technology capable of simultaneously detecting up to 10 targets in a single reaction while maintaining high levels of sensitivity, specificity, and robustness. This technology enables the development of comprehensive, flexible diagnostic panels that can be deployed across multiple analytical platforms, supporting infectious disease diagnosis, epidemiological surveillance, and a broad range of clinical applications. In parallel, we develop next-generation sequencing (NGS) solutions to further expand the capabilities of molecular diagnostics and genomic characterization.

Pharmacogenomics and Personalized Medicine

We develop NGS-based solutions for the analysis of genetic variants that influence individual responses to drug therapies, enabling more informed treatment selection, improved therapeutic outcomes, and reduced adverse drug reactions, ultimately supporting the implementation of personalized medicine.

Technologies for Nucleic Acid Therapeutics

We develop next-generation lipid nanoparticles (LNPs) for the targeted delivery of nucleic acid therapeutics. Our research focuses on the design of novel ionizable lipids and advanced formulations incorporating passive and active targeting strategies, including ligand conjugation to selectively deliver therapeutic cargo to specific organs, tissues, and cell populations. These technologies are designed to unlock the full therapeutic potential of RNA-based medicines by improving delivery efficiency, precision, and safety.

Bioinformatics and Computational Intelligence

Bioinformatics is a key enabler across our research activities. We develop computational tools, advanced algorithms, and artificial intelligence solutions to support the design and optimization of molecular diagnostic technologies, genomic data analysis, and next-generation sequencing applications. We also apply computational modelling and de novo design approaches to identify novel ligands for active targeting strategies in nucleic acid therapeutics.